已收盘 12-19 16:00:00 美东时间
-0.520
-0.42%
Zoetis (ZTS) priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 in a private offering to qualified institutional buyers. T...
12-16 16:15
Substantially All of Net Proceeds Expected to Be Used to Repurchase Approximately $1.6 Billion of Common Stock and for Capped Call Transactions
12-16 14:42
根据《兽药管理条例》和《兽药注册办法》规定,经审查,批准英特威美国分公司生产的鸡传染性喉气管炎活疫苗(LT-IVAX株)等2种兽药产品在我国再注册,核发《进口兽...
12-11 00:00
今日重点评级关注:Chardan Capital:维持Senti Biosciences"买入"评级,目标价从12美元升至13美元;Guggenheim:维持Praxis Precision Medicine"买入"评级,目标价从540美元升至760美元
12-10 10:33
Zoetis Inc's (NYSE:ZTS) short interest as a percent of float has fallen 25.5% s...
12-09 03:00
今日重点评级关注:Guggenheim:维持Cybin Inc. Common Shares"买入"评级,目标价从39美元升至48美元;HC Wainwright & Co.:维持Capricor Therapeutics"买入"评级,目标价从24美元升至60美元
12-04 09:38
BTIG analyst Mark Massaro reiterates Zoetis (NYSE:ZTS) with a Buy and maintains $160 price target.
12-03 18:40
Can-Fite BioPharma will attend BioFIT 2025 to seek partnerships for its Phase III cancer drug Namodenoson, targeting the $3.1 billion veterinary oncology market. The company also develops Piclidenoson for pet osteoarthritis, a $3 billion market. Can-Fite previously partnered with Vetbiolix for Piclidenoson, potential $325M in royalties. At BioFIT, Can-Fite will meet Elanco and Zoetis to explore Namodenoson collaborations, leveraging its strong an...
11-24 12:00